Henagliflozin, a diabetes treatment approved in China, may do more than just control blood sugar—it may actually slow biological aging. Long prescribed to patients with type 2 diabetes to manage glucose, this drug is now drawing attention after clinical trials in China revealed measurable shifts in blood markers and cellular function linked to slower aging. […]
